Skip to main content
Medpace Holdings, Inc. logo

Medpace Holdings, Inc. — Investor Relations & Filings

Ticker · MEDP ISIN · US58506Q1094 LEI · 549300H8TYEUVTW14A54 US Professional, scientific and technical activities
Open in API
Filings indexed 858 across all filing types
Latest filing 2023-04-04 Director's Dealing
Country US United States of America
Listing US MEDP

About Medpace Holdings, Inc.

https://investor.medpace.com/

Medpace Holdings, Inc. is a scientifically-driven, global, full-service clinical contract research organization (CRO) that provides Phase I-IV clinical development services. The company serves the biotechnology, pharmaceutical, and medical device industries, with a mission to accelerate the development of safe and effective medical therapeutics. Medpace employs a disciplined operating approach that leverages regulatory and therapeutic expertise. Its services include clinical pharmacology, central laboratory, bioanalytical, ECG core lab, and imaging core labs. The company has expertise across major therapeutic areas, including oncology, cardiology, metabolic disease, endocrinology, central nervous system, and anti-viral and anti-infective diseases.

Recent filings

Filing Released Lang Actions
Director's Dealing 2023
Director's Dealing
2023-04-04 English
Director's Dealing 2023
Director's Dealing
2023-04-04 English
8-K
Capital/Financing Update Classification · 100% confidence The document is a Form 8-K filed with the SEC, titled 'Current Report' and dated March 31, 2023. It reports the entry into Amendment No. 5 to Loan Documents related to the company's unsecured credit facility, including changes to borrowing limits, interest rates, and expiration dates. The document includes a description of the amendment and references an exhibit containing the amendment itself. There are no financial statements or comprehensive financial data presented, only a disclosure of a material definitive agreement related to financing. This fits the category of a Capital/Financing Update, as it updates on the company's financing activities and credit facility terms. The document length is under 5,000 characters and contains substantive information about financing, not just an announcement or certification. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2023-03-31 English
FORM 4
Director's Dealing
2023-02-22 English
FORM 4
Director's Dealing
2023-02-22 English
FORM 4
Director's Dealing
2023-02-22 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.